Replies to post #234500 on Biotech Values

[dewophile]

While FGEN is up significantly (not surprising and congrats to longs) there is still some potential risk for Roxa in NDD based on the AKBA data if docs think there could be some class effect, especially since the safety endpoints for the NDD population, while meeting non inferiority boundaries, were numerically worse than placebo


http://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-positive-phase-3-pooled-roxadustat-safety-and

Edit: FGEN was up over 10 percent when I checked and posted. I see now it is modestly lower. I would guess the market is trying to digest the implications for Roxa and not so black and white